← Back to Search
Effects Of COX‐2 Inhibition On Spinal Nociception: The Role Of Endocannabinoids
L. E. Staniaszek, L. Norris, D. Kendall, D. Barrett, V. Chapman
Published 2010 · Chemistry, Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
Background and purpose: Recent studies suggest that the effects of cyclooxygenase‐2 (COX‐2) inhibition are mediated by cannabinoid receptor activation. However, some non‐steroidal anti‐inflammatory drugs inhibit the enzyme fatty acid amide hydrolase, which regulates levels of some endocannabinoids. Whether COX‐2 directly regulates levels of endocannabinoids in vivo is unclear. Here, the effect of the COX‐2 inhibitor nimesulide, which does not inhibit fatty acid amide hydrolase, on spinal nociceptive processing was determined. Effects of nimesulide on tissue levels of endocannabinoids and related compounds were measured and the role of cannabinoid 1 (CB1) receptors was determined.
This paper references
Differential Sensitivity and Mechanism of Inhibition of COX-2 Oxygenation of Arachidonic Acid and 2-Arachidonoylglycerol by Ibuprofen and Mefenamic Acid†
J. J. Prusakiewicz (2009)
Acidic Nonsteroidal Anti-inflammatory Drugs Inhibit Rat Brain Fatty Acid Amide Hydrolase in a pH-dependent Manner
C. Fowler (2003)
Spinal Prostaglandins Are Involved in the Development But Not the Maintenance of Inflammation-Induced Spinal Hyperexcitability
E. Vásquez (2001)
Lipoxygenase-catalyzed oxygenation of arachidonylethanolamide, a cannabinoid receptor agonist.
N. Ueda (1995)
Ibuprofen inhibits the metabolism of the endogenous cannabimimetic agent anandamide.
C. Fowler (1997)
Oxygenation of the Endocannabinoid, 2-Arachidonylglycerol, to Glyceryl Prostaglandins by Cyclooxygenase-2*
K. Kozak (2000)
Human platelets and polymorphonuclear leukocytes synthesize oxygenated derivatives of arachidonylethanolamide (anandamide): their affinities for cannabinoid receptors and pathways of inactivation.
W. Edgemond (1998)
Synthesis of Prostaglandin E2 Ethanolamide from Anandamide by Cyclooxygenase-2*
M. Yu (1997)
Quantitative assessment of tactile allodynia in the rat paw
S. Chaplan (1994)
Identification of Novel Endogenous Cytochrome P450 Arachidonate Metabolites with High Affinity for Cannabinoid Receptors*
J. Chen (2008)
Blockade of Endocannabinoid-Degrading Enzymes Attenuates Neuropathic Pain
S. Kinsey (2009)
Neuropathic pain and the endocannabinoid system in the dorsal raphe: pharmacological treatment and interactions with the serotonergic system
E. Palazzo (2006)
Spinal antinociceptive effects of cyclooxygenase inhibition during inflammation: Involvement of prostaglandins and endocannabinoids
A. Telleria-Diaz (2010)
Activation of peripheral cannabinoid receptors attenuates cutaneous hyperalgesia produced by a heat injury
L. Johanek (2004)
Quantitative profiling of endocannabinoids and related compounds in rat brain using liquid chromatography-tandem electrospray ionization mass spectrometry.
D. Richardson (2007)
Reversible Inhibitors of Fatty Acid Amide Hydrolase That Promote Analgesia: Evidence for an Unprecedented Combination of Potency and Selectivity
A. Lichtman (2004)
A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation.
T. Dinh (2002)
A role for endocannabinoids in indomethacin-induced spinal antinociception.
H. Gühring (2002)
Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury: a comparison of nimesulide and naproxen
A. Shah (2001)
Cyclooxygenases 1 and 2.
J. Vane (1998)
The effect of cannabidiol on mouse hepatic microsomal cytochrome P450-dependent anandamide metabolism.
L. Bornheim (1993)
Inhibition of cyclooxygenase-2 elicits a CB1-mediated decrease of excitatory transmission in rat CA1 hippocampus
K. Slanina (2005)
Analgesic Effects of Fatty Acid Amide Hydrolase Inhibition in a Rat Model of Neuropathic Pain
M. Jhaveri (2006)
The Endocannabinoid Anandamide Is a Substrate for the Human Polymorphic Cytochrome P450 2D6
Natasha T Snider (2008)
Brain monoglyceride lipase participating in endocannabinoid inactivation
T. V. Dinh (2002)
Inhibition of fatty acid amide hydrolase, a key endocannabinoid metabolizing enzyme, by analogues of ibuprofen and indomethacin.
S. Holt (2007)
Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats
S. Petrosino (2007)
Oxidative metabolism of endocannabinoids by COX-2.
K. Kozak (2004)
The Acute Antihyperalgesic Action of Nonsteroidal, Anti-Inflammatory Drugs and Release of Spinal Prostaglandin E2 Is Mediated by the Inhibition of Constitutive Spinal Cyclooxygenase-2 (COX-2) but not COX-1
T. Yaksh (2001)
Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides
B. Cravatt (1996)
Effects of nimesulide, acetylsalicylic acid, ibuprofen and nabumetone on cyclooxygenase-1- and cyclooxygenase-2-mediated prostanoid production in healthy volunteers ex vivo.
Markku Kerola (2009)
Prostaglandin E2 glycerol ester, an endogenous COX‐2 metabolite of 2‐arachidonoylglycerol, induces hyperalgesia and modulates NFκB activity
S. Hu (2008)
Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase
B. Cravatt (2001)
Inhibition of anandamide hydrolysis by the enantiomers of ibuprofen, ketorolac, and flurbiprofen.
C. Fowler (1999)
Constitutive Spinal Cyclooxygenase-2 Participates in the Initiation of Tissue Injury-Induced Hyperalgesia
J. Ghilardi (2004)
A Cytochrome P450-Derived Epoxygenated Metabolite of Anandamide Is a Potent Cannabinoid Receptor 2-Selective Agonist
Natasha T Snider (2009)
Spinal GABAB-receptor antagonism increases nociceptive transmission in vivo
D. M. Sokal (2001)
Guide to Receptors and Channels (GRAC), 3rd edition
S. Alexander (2008)
Synergistic antinociceptive effects of anandamide, an endocannabinoid, and nonsteroidal anti-inflammatory drugs in peripheral tissue: a role for endogenous fatty-acid ethanolamides?
J. Guindon (2006)
Cytochrome P-450 metabolites of 2-arachidonoylglycerol play a role in Ca2+-induced relaxation of rat mesenteric arteries.
Emmanuel M. Awumey (2008)
Cannabinoid receptors and pain
R. Pertwee (2001)
The Cellular Uptake of Anandamide Is Coupled to Its Breakdown by Fatty-acid Amide Hydrolase*
D. Deutsch (2001)
Anandamide Metabolism by Human Liver and Kidney Microsomal Cytochrome P450 Enzymes to Form Hydroxyeicosatetraenoic and Epoxyeicosatrienoic Acid Ethanolamides
Natasha T Snider (2007)
Anandamide hydroxylation by brain lipoxygenase:metabolite structures and potencies at the cannabinoid receptor.
A. Hampson (1995)
In vitro and in vivo pharmacological evidence of selective cyclooxygenase-2 inhibition by nimesulide: An overview
J. Famaey (1997)
Formation of prostamides from anandamide in FAAH knockout mice analyzed by HPLC with tandem mass spectrometry Published, JLR Papers in Press, January 16, 2004. DOI 10.1194/jlr.M300475-JLR200
A. Weber (2004)
Cannabinoids: a real prospect for pain relief?
L. Iversen (2002)
Expression and purification of orphan cytochrome P450 4X1 and oxidation of anandamide
Katarina Stark (2008)
This paper is referenced by
Peripheral FAAH inhibition causes profound antinociception and protects against indomethacin-induced gastric lesions.
O. Sasso (2012)
Molecular Understanding of the Activation of CB1 and Blockade of TRPV1 Receptors: Implications for Novel Treatment Strategies in Osteoarthritis
J. Mlost (2018)
Control of analgesic and anti-inflammatory pathways by fatty acid amide hydrolase
J. Long (2012)
Metabolomics of postprandial plasma alterations: a comprehensive Japanese study
T. Moriya (2018)
Discovery of Prostamide F2α and Its Role in Inflammatory Pain and Dorsal Horn Nociceptive Neuron Hyperexcitability
Luisa Gatta (2012)
Inhibitory properties of ibuprofen and its amide analogues towards the hydrolysis and cyclooxygenation of the endocannabinoid anandamide
C. Fowler (2013)
The fatty acid amide hydrolase and cyclooxygenase-inhibitory properties of novel amide derivatives of carprofen.
Alessandro Deplano (2020)
NSAIDs: eNdocannabinoid stimulating anti-inflammatory drugs?
C. Fowler (2012)
Peripheral changes of endocannabinoid system components in episodic and chronic migraine patients: A pilot study.
R. Greco (2020)
Substrate-selective COX-2 inhibition decreases anxiety via endocannabinoid activation
D. J. Hermanson (2013)
Non-opioid Analgesics and the Endocannabinoid System
R. D. Topuz (2020)
Controlling 2-arachidonoylglycerol metabolism as an anti-inflammatory strategy.
Mireille Alhouayek (2014)
Endocannabinoid involvement in endometriosis
N. Dmitrieva (2010)
The role of bioactive lipids in pain and inflammation
A. Wong (2012)
Endocannabinoid Oxygenation by Cyclooxygenases, Lipoxygenases, and Cytochromes P450: Cross-Talk between the Eicosanoid and Endocannabinoid Signaling Pathways
C. Rouzer (2011)
Simultaneous tissue profiling of eicosanoid and endocannabinoid lipid families in a rat model of osteoarthritis[S]
Amy Wong (2014)
Arsenic reduces the antipyretic activity of paracetamol in rats: modulation of brain COX-2 activity and CB₁ receptor expression.
K. Vijayakaran (2014)
Substrate-selective COX-2 inhibition as a novel strategy for therapeutic endocannabinoid augmentation.
D. J. Hermanson (2014)
Cellular sources of cyclooxygenase‐1 and ‐2 up‐regulation in the spinal dorsal horn after spinal nerve ligation
Y. Lau (2014)
Pharmacological Aspects of Anandamide and 2-Arachidonoyglycerol as Bioactive Lipids
Mireille Alhouayek (2017)
Cannabinoid system and cyclooxygenases inhibitors
H. Păunescu (2011)
COX‐2 is required for the modulation of spinal nociceptive information related to ephrinB/EphB signalling
X. Zhou (2015)
Influence of nitric oxide synthase or cyclooxygenase inhibitors on cannabinoids activity in streptozotocin-induced neuropathy.
M. Bujalska-Zadrożny (2015)
Inhibitory effects of aspirin-triggered resolvin D1 on spinal nociceptive processing in rat pain models
P. Meesawatsom (2016)
COX-2-derived endocannabinoid metabolites as novel inflammatory mediators.
Mireille Alhouayek (2014)
The Potential of Inhibitors of Endocannabinoid Metabolism for Drug Development: A Critical Review.
C. Fowler (2015)